More Images
Treatment with the antiviral remdesivir (Veklury) plus dexamethasone was linked to fewer deaths among patients hospitalized for COVID-19 compared with dexamethasone monotherapy, a retrospective study suggested.

Using propensity score matching, the drug duo was associated with an overall 26% reduction in mortality at 14 days and an overall 24% reduction at 28 days when compared with dexamethasone alone, reported Andre Kalil, MD, MPH, of the University of Nebraska Medical Center in Omaha, and colleagues in Clinical Infectious Diseases.

Of note, remdesivir plus dexamethasone was tied to a decreased risk of mortality at 14 days across all baseline oxygen requirements, when compared with dexamethasone monotherapy. Head over to MedPage Today to read more about it.